[Treatment of idiopathic pulmonary fibrosis]

Dominique Valeyre, Geneviève Dion
Bulletin de L'Académie Nationale de Médecine 2010, 194 (2): 367-81; discussion 381-2
Idiopathic pulmonary fibrosis (IPF) is a severe disease with a median survival time of only 24-36 months. It is characterized by inexorably progressive respiratory failure and by acute exacerbations that are often rapidly fatal. The standard treatment based on steroids and immunosuppressive drugs is no longer recommended Lung transplantation is the only treatment with an impact on survival but it concerns only a minority of patients and must be performed early in the disease process. Patients not eligible for transplantation should be given the opportunity to participate in clinical trials of promising new therapies. Many trials have recently been completed or are currently underway, but few results have been published. In the meantime, supportive treatment (oxygen therapy and rehabilitation), vaccination, and treatment of comorbidities (gastroesophageal reflux, sleep apnea) are recommended.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"